CLLS:NSD-Cellectis S.A (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.82

Change

-0.46 (-3.01)%

Market Cap

USD 0.67B

Volume

0.41M

Average Target Price

USD 39.00 (+163.16%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-2.81 (-1.84%)

USD61.31B 102.33 81.58
VRTX Vertex Pharmaceuticals Incorpo..

+1.67 (+0.79%)

USD55.06B 20.27 14.23
REGN Regeneron Pharmaceuticals, Inc

+10.03 (+1.98%)

USD54.03B 14.44 11.17
BNTX BioNTech SE

-5.34 (-2.87%)

USD47.83B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.34 (+0.78%)

USD38.01B 55.82 39.93
BGNE BeiGene, Ltd

-3.87 (-1.24%)

USD27.16B N/A N/A
SGEN Seagen Inc

-0.06 (-0.04%)

USD26.27B 40.39 34.48
RPRX Royalty Pharma plc

-0.40 (-0.99%)

USD24.64B 22.60 15.13
GMAB Genmab A/S

+0.37 (+1.02%)

USD24.15B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.23% 8% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.23% 8% F 5% F
Trailing 12 Months  
Capital Gain -14.88% 38% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.88% 38% F 12% F
Trailing 5 Years  
Capital Gain -50.60% 34% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.60% 34% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 7.20% 44% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.20% 43% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 45.40% 70% C- 39% F
Risk Adjusted Return 15.87% 44% F 37% F
Market Capitalization 0.67B 64% D 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.61 70% C- 55% F
Price / Cash Flow Ratio -8.31 53% F 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.20% 68% D+ 27% F
Return on Invested Capital -25.61% 74% C 26% F
Return on Assets -16.35% 72% C- 23% F
Debt to Equity Ratio 10.46% 56% F 72% C-
Technical Ratios  
Short Ratio 3.67 56% F 41% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.24 13% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector